Adulteration and Controversial Herbal Drugs: Implications for Safety, Efficacy, and Regulatory Challenges

Abstract

Herbal medicines are widely used across the world due to their perceived safety, affordability, and therapeutic potential. However, adulteration and the presence of controversial herbal drugs have emerged as serious concerns affecting their safety, efficacy, and public trust. Adulteration may occur intentionally for economic gain or unintentionally through misidentification, contamination, or substitution. Moreover, certain herbs classified as controversial raise ethical and regulatory dilemmas due to toxicity, endangered status, or unclear pharmacological profiles. Methods: This review synthesizes findings from recent scientific studies, pharmacovigilance reports, and regulatory documents related to adulteration and controversial herbal formulations. Data were analyzed to assess patterns of adulteration, reported adverse effects, and the effectiveness of existing quality control and regulatory frameworks. Results: Evidence indicates that adulteration is prevalent in herbal markets globally, involving the substitution of authentic herbs with cheaper or morphologically similar species, addition of synthetic drugs, and contamination with heavy metals or pesticides. Controversial herbs such as Aconitum, Ephedra, and Cannabis exhibit both therapeutic and toxic potential, necessitating strict dosage and preparation control. The lack of standardized identification methods, weak regulatory enforcement, and inadequate labeling practices further compromise product safety and therapeutic reliability. Discussion: The findings highlight the urgent need for advanced analytical authentication tools (HPTLC, DNA barcoding, LC-MS), improved cultivation and sourcing practices, and harmonization of global regulatory policies. Educational initiatives for practitioners and consumers are also essential to minimize misuse and enhance pharmacovigilance. Conclusion: Adulteration and controversial herbal drugs pose significant safety and efficacy challenges. Strengthening quality assurance systems and implementing robust, science-based regulations are crucial for ensuring the safe and effective use of herbal medicines in modern healthcare.

Introduction

Herbal medicines have been widely used for centuries, with approximately 80% of the global population relying on them for primary healthcare. The global surge in herbal product use has highlighted major challenges related to adulteration—including substitution, contamination, synthetic drug addition, and dilution—and the use of controversial herbs such as Aconitum, Ephedra, Cannabis, Aristolochia, and Nux Vomica, which carry safety, toxicity, or legal concerns.

Adulteration and misuse not only reduce therapeutic efficacy but also pose serious public health risks, including organ toxicity and fatal outcomes. Regulatory gaps persist worldwide due to inconsistent enforcement, lack of standardized testing, insufficient pharmacovigilance, and fragmented classification of herbal products as foods, drugs, or supplements.

Modern analytical and authentication techniques like HPTLC, LC-MS, DNA barcoding, and FTIR spectroscopy can significantly improve quality control, though cost and accessibility remain barriers in developing countries. Addressing these challenges requires robust regulatory frameworks, sustainable sourcing practices, practitioner education, and consumer awareness to ensure the safety, efficacy, and ethical use of herbal medicines globally.

Conclusion

Adulteration and the use of controversial herbal drugs present multifaceted challenges that threaten the credibility, safety, and therapeutic integrity of traditional and modern herbal medicine. The issues stem from a combination of economic incentives, weak regulation, inadequate analytical control, and lack of public awareness. To safeguard consumer health and sustain the global herbal industry, a multilayered approach is required: Regulatory harmonization: Global standards for identification, labeling, and safety testing must be unified under WHO and regional frameworks. Advanced authentication technologies: Routine implementation of HPTLC, DNA barcoding, and LC-MS in both pre-market and post-market surveillance. Strengthened pharmacovigilance: Establishment of integrated reporting systems for herbal adverse effects. Education and transparency: Training of practitioners, manufacturers, and consumers on safe usage, dosage, and recognition of genuine products. Ethical and sustainable sourcing: Promotion of certified cultivation and conservation of medicinal plants. Herbal medicine represents a valuable therapeutic heritage that, if safeguarded with scientific rigor and ethical responsibility, can continue to serve humanity as a bridge between tradition and modern healthcare. Ensuring its purity, safety, and authenticity is not merely a regulatory obligation but a moral imperative for the preservation of public health and cultural legacy.

References

[1] Chen et al. (2025) Comparative analysis of Chinese classical prescriptions and global traditional polyherbal formulationsJournal: Chinese Medicine, Volume 20, Article 169 Publisher: BioMed Central. [2] WHO Global Report on Traditional and Complementary Medicine 2019 Publisher: World Health Organization (WHO), Geneva ISBN: 978-92-4-151543-6 Page Reference: Page 10 (Executive Summary). [3] WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems Publisher: World Health Organization (WHO), Geneva Year: 2004 ISBN: 9241592214.Page Reference: Pages 13–22. [4] Happy et al. (2025) The pharmacology, toxicology, and detoxification of Aconitum kusnezoffii: traditional and modern views Journal: Applied Biological Chemistry, Vol. 68, Article 8 Publisher: SpringerOpen. [5] Neha Hande et al. (2025) Chromatographic Fingerprinting of Medicinal Plants: A Reliable Tool for Quality Control Journal: International Journal of Pharmaceutical Sciences Volume: 3, Issue 10 Pages: 538–553 Publisher: Shri Swami Samarth Institute of Pharmacy [6] WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems Publisher: World Health Organization (WHO), Geneva Year: 2004 ISBN: 9241592214 Page Reference: Pages 17–22. [7] Navale et al. (2024 Review on Adulterations in Herbal Formulation Journal: International Journal of Pharmacy and Herbal Technology, Vol. 2, Issue 1Pages: 758–772. [8] WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems Publisher: World Health Organization (WHO), Geneva Year: 2004 ISBN: 9241592214 Page Reference: Pages 13–22 [9] Source: Awari et al. (2025) Vatsanabha (Aconitum Ferox): A Review of Its Toxicity and Therapeutic Potential in Ayurveda Journal: International Journal of Creative Research Thoughts (IJCRT) Volume: 13, Issue 9 Pages: 1–10. [10] Source: FDA Final Ruling on Ephedra (2004) Federal Register, Vol. 69, No. 28 Pages: 6787–6854. [11] Source: Simiyu et al. (2022) Understanding Cannabis sativa L.: Current Status of Propagation, Use, Legalization Journal: Plants, Vol. 11, Issue 9 Pages: Article 1236 [12] Source: Anger et al. (2020) Aristolochic Acid-Induced Nephrotoxicity: Molecular Mechanisms and Protective Approaches Journal: International Journal of Molecular Sciences, Vol. 21, Issue 3 Pages: Article 1157 [13] Source: Mishra & Patil (2024) Ayurvedic Toxicological Review of Kuchla (Strychnos nux-vomica) Journal: Journal of Pharmacognosy and Phytochemistry, Vol. 13, Issue 3 Pages: 86–88 [14] WHO-GMP Guidelines for Herbal Medicine Document: WHO Guidelines on Good Manufacturing Practices (GMP) for Herbal Medicines Publisher: World Health Organization (WHO), Geneva Year: 2007 ISBN: 9789241547161 Page Reference: Pages 5–12 [15] Hande et al. (2025) Chromatographic Fingerprinting of Medicinal Plants: A Reliable Tool for Quality Control Journal: International Journal of Pharmaceutical Sciences, Vol. 3, Issue 10 Pages: 538–553 Publisher: Shri Swami Samarth Institute of Pharmacy. [16] WHO Traditional Medicine Strategy 2014–2023 Publisher: World Health Organization (WHO), Geneva ISBN: 978-92-4-150609-0 Page Reference: Pages 7–15 [17] Hande et al. (2025) Chromatographic Fingerprinting of Medicinal Plants: A Reliable Tool for Quality Control Journal: International Journal of Pharmaceutical Sciences, Vol. 3, Issue 10 Pages: 538–553.

Copyright

Copyright © 2025 Dr. Arvind Kumar, Dr. Vikas Kumar Baletiya. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.